查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1855972

2025年全球罕見血液疾病市場報告

Rare Hematology Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，罕見血液疾病市場規模呈現強勁成長，預計從2024年的144.6億美元成長到2025年的154.7億美元，複合年成長率達7.0%。這一成長主要受以下因素驅動：專科治療中心數量增加、血液病學學術研究經費成長、醫生對罕見血液病的認知提高、生物樣本庫和登記庫的使用日益增多，以及由於監測系統加強而導致的病例報告改進。

預計未來幾年，罕見血液疾病市場將保持強勁成長，到2029年市場規模將達到199.8億美元，複合年成長率（CAGR）為6.6%。預測期內的成長將主要得益於靶向生技藥品研發管線的不斷拓展、精準診斷技術的日益普及、罕見病研究領域跨境合作的不斷深化、患者支持數位平台的研發以及對預防性遺傳諮詢的日益重視。預測期內的關鍵趨勢包括免疫療法的進步、幹細胞移植技術的改進、數位健康平台在血液疾病領域的應用、技術主導的藥物研發模式以及基於生物標記的診斷方法的開發。

預計未來幾年，罕見血液疾病盛行率的不斷上升將推動罕見血液疾病市場的成長。罕見血液疾病是指影響血球和凝血因子生成、功能和壽命的罕見疾病，會導致貧血、出血和溶血。這些疾病的盛行率上升主要是由於基因突變和遺傳性疾病，即異常基因從父母遺傳給子女。罕見血液疾病市場在應對這些疾病方面發揮關鍵作用，提供專業的診斷和標靶治療，以有效管理複雜罕見的血液疾病。這些服務能夠實現標靶治療和持續的患者照護，減少併發症，最終改善患者的健康狀況和生活品質。例如，總部位於澳洲的非營利組織珀斯血液研究所於2024年4月報告稱，被診斷患有血友病（一種影響血液凝固的遺傳性血液疾病）的人數從2021年的233,577人增加到2022年的257,146人。因此，罕見血液疾病盛行率的上升正在推動罕見血液疾病市場的擴張。

罕見血液疾病領域的公司正日益專注於開發創新治療方法，並建立策略性舉措，例如成立多方相關利益者倡導委員會，以滿足未被滿足的醫療需求、加強患者支持並推進各種疾病的解決方案。多方利害關係人倡導委員會匯集患者、看護者和專家，共同合作，改善特定疾病的照護、提高公眾意識並尋求解決方案。例如，2023年2月，美國生物製藥公司Agios 相關利益者推出了「紅血球革命計劃諮詢委員會」。該委員會專注於罕見溶血性貧血，包括丙酮酸激酶缺乏症、地中海貧血和鐮狀細胞貧血。委員會旨在加強社區聯繫、發表研究證據、提出切實可行的解決方案，並提高公眾對通用挑戰的認知。這包括贊助播客、製作影片內容，以及與美國國家罕見疾病組織等機構夥伴關係，以促進健康公平和教育。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅，以及新冠疫情及其復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球罕見血液疾病：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 終端用戶產業分析
  • 全球罕見血液疾病市場：成長率分析
  • 全球罕見血液疾病市場表現：規模與成長，2019-2024年
  • 全球罕見血液疾病市場預測：規模與成長，2024-2029年，2034年
  • 全球罕見血液疾病：潛在市場規模 (TAM)

第6章 市場細分

  • 全球罕見血液疾病市場依疾病類型、表現及預測分類，2019-2024年、2024-2029年、2034年
  • 血友病
  • 鐮狀細胞性貧血症
  • 地中海型貧血
  • 骨髓發育不良症候群
  • 其他疾病類型
  • 全球罕見血液疾病市場依治療類型分類：績效及預測，2019-2024年、2024-2029年、2034年
  • 基因治療
  • 幹細胞移植
  • 輸血
  • 藥物治療
  • 全球罕見血液疾病市場（依診斷技術分類）：績效及預測，2019-2024年、2024-2029年、2034年
  • 實驗室測試
  • 血液檢查
  • 骨髓切片檢查
  • 成像技術
  • 磁振造影（MRI）掃描
  • 超音波
  • 基因檢測
  • 攜帶者篩檢
  • 全基因組定序
  • 全球罕見血液疾病市場按應用、效能和預測分類，2019-2024年、2024-2029年、2034年
  • 兒童
  • 成人
  • 全球罕見血液疾病市場依最終用戶、績效及預測分類，2019-2024年、2024-2029年、2034年
  • 醫院
  • 專科診所
  • 研究所
  • 全球罕見血液疾病市場：依血友病類型細分、績效及預測（2019-2024年、2024-2029年、2034年）
  • A型血友病A
  • B型血友病
  • 血友病C
  • 後天性血友病
  • 全球罕見血液疾病市場：鐮狀細胞疾病、類型、表現和預測進行細分，2019-2024年、2024-2029年、2034年
  • 鐮狀細胞貧血症
  • 鐮狀血紅素C疾病
  • 鐮狀細胞BETA-地中海貧血
  • 全球罕見血液疾病市場：依地中海型貧血類型細分、績效及預測（2019-2024年、2024-2029年、2034年）
  • α-地中海貧血
  • BETA-地中海型貧血
  • 全球罕見血液疾病市場：細分市場（骨髓發育不良症候群症候群），依類型、療效及預測（2019-2024年、2024-2029年、2034年）
  • 難治性貧血（RA）
  • 伴隨環狀鐵粒幼細胞的難治性貧血（RARS）
  • 難治性多系發育不良性血球減少症（RCMD）
  • 難治性貧血伴隨原細胞增多（RAEB）
  • 伴隨孤立性 Del(5Q) 的骨髓發育不良症候群
  • 未分類骨髓發育不良症候群
  • 全球罕見血液疾病市場：依其他疾病類型細分，實際數據與預測，2019-2024年、2024-2029年、2034年
  • 再生障礙性貧血
  • 陣發性夜間血尿症
  • 罕見凝血障礙

第7章 區域和國家分析

  • 全球罕見血液疾病市場：依地區、績效及預測分類，2019-2024年、2024-2029年、2034年
  • 全球罕見血液疾病市場：國家、表現及預測，2019-2024年、2024-2029年、2034年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 罕見血液疾病市場：競爭格局
  • 罕見血液疾病市場：公司簡介
    • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Novartis AG
  • Astrazeneca Plc
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • CSL Behring LLC
  • Biogen Inc.
  • Jazz Pharmaceuticals Plc
  • Octapharma AG
  • PharmaEssentia Corporation
  • Disc Medicine Inc.
  • BioInvent International AB
  • Mustang Bio Inc.
  • BlueSphere Bio Inc.
  • Rallybio LLC

第32章 全球市場競爭基準化分析與儀錶板

第33章 重大併購

第34章 近期市場趨勢

第35章：高潛力市場國家、細分市場與策略

  • 2029年罕見血液疾病市場：蘊藏新機會的國家
  • 2029年罕見血液疾病市場：新興細分市場機會
  • 2029年罕見血液疾病市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章附錄

簡介目錄
Product Code: r38624

Rare hematology refers to the study, diagnosis, and treatment of uncommon blood disorders, including rare anemias, clotting disorders, bone marrow failure syndromes, and rare blood cancers. These conditions often affect small patient populations and have limited treatment options. Rare hematology advances understanding, improves diagnosis, and supports the development of targeted therapies to enhance patient outcomes and quality of life.

The primary disease types in rare hematology include hemophilia, sickle cell disease, thalassemia, myelodysplastic syndromes, and others. Hemophilia is a genetic bleeding disorder characterized by insufficient clotting factors, leading to excessive bleeding and difficulty controlling hemorrhages. Treatments include gene therapy, stem cell transplantation, blood transfusion, and pharmacotherapy, supported by diagnostic techniques such as laboratory tests, blood tests, bone marrow biopsies, imaging methods, MRI scans, ultrasounds, genetic testing, carrier screening, and whole genome sequencing. Applications span both pediatric and adult populations, serving end users including hospitals, specialty clinics, and research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The rare hematology market research report is one of a series of new reports from The Business Research Company that provides rare hematology market statistics, including rare hematology industry global market size, regional shares, competitors with a rare hematology market share, detailed rare hematology market segments, market trends and opportunities, and any further data you may need to thrive in the rare hematology industry. This rare hematology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rare hematology market size has grown strongly in recent years. It will grow from $14.46 billion in 2024 to $15.47 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period was driven by increasing availability of specialized treatment centers, rising academic research funding in hematology, growing physician awareness of rare blood conditions, expanding use of biobanking and registries, and improved incidence reporting through enhanced surveillance systems.

The rare hematology market size is expected to see strong growth in the next few years. It will grow to $19.98 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period is fueled by a growing pipeline of targeted biologics, rising adoption of precision diagnostics, expanding cross-border collaborations for rare disease research, development of digital platforms for patient support, and increasing emphasis on preventive genetic counseling. The primary trends in the forecast period include advancements in immunotherapy approaches, improvements in stem cell transplantation methods, integration of digital health platforms in hematology, technology-driven drug discovery models, and developments in biomarker-based diagnostics.

The increasing prevalence of rare blood disorders is expected to drive the growth of the rare hematology market in the coming years. Rare blood disorders are uncommon conditions that affect the production, function, or lifespan of blood cells or clotting factors, leading to anemia, bleeding, or hemolysis. The rising prevalence of these disorders is primarily due to genetic mutations and inherited conditions, where abnormal genes are passed down from parents to children. The rare hematology market plays a crucial role in addressing these conditions by providing specialized diagnostics and targeted therapies, ideal for managing complex and uncommon blood disorders. These services reduce complications by enabling precise treatment and continuous patient care, ultimately improving health outcomes and quality of life. For example, in April 2024, the Perth Blood Institute, an Australia-based nonprofit, reported that the number of people diagnosed with hemophilia, a genetic blood disorder that impairs blood clotting, increased to 257,146 in 2022 from 233,577 in 2021. As a result, the growing prevalence of rare blood disorders is fueling the expansion of the rare hematology market.

Companies in the rare hematology market are increasingly focusing on developing innovative therapies and establishing strategic initiatives, such as multi-stakeholder advocacy councils, to address unmet medical needs, enhance patient support, and drive solutions across various conditions. Multi-stakeholder advocacy councils bring together patients, caregivers, and experts to collaborate on improving care, awareness, and solutions for specific health conditions. For instance, in February 2023, Agios Pharmaceuticals Inc., a US-based biopharmaceutical company, launched the Red Cell Revolution advocacy advisory council. This initiative focuses on rare hemolytic anemias, including pyruvate kinase deficiency, thalassemia, and sickle cell disease. The council aims to strengthen community connections, generate published evidence, create practical solutions, and raise awareness of common challenges. It includes initiatives such as sponsored podcasts, video content, and partnerships with organizations such as the National Organization for Rare Disorders to promote health equity and education.

In October 2022, Pfizer Inc., a US-based biopharmaceutical company, acquired Global Blood Therapeutics Inc. for an undisclosed amount. This acquisition allows Pfizer to expand its rare hematology portfolio, particularly in sickle cell disease, enhancing its pipeline of therapies for underserved patient populations. Global Blood Therapeutics Inc. is a US-based biopharmaceutical company focused on developing therapies for rare blood disorders, especially sickle cell disease.

Major players in the rare hematology market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Abbvie Inc., Bayer AG, Sanofi S.A., Novartis AG, Astrazeneca Plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Amgen Inc., CSL Behring LLC, Biogen Inc., Jazz Pharmaceuticals Plc, Octapharma AG, PharmaEssentia Corporation, Disc Medicine Inc., BioInvent International AB, Mustang Bio Inc., BlueSphere Bio Inc., and Rallybio LLC.

North America was the largest region in the rare hematology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rare hematology report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rare hematology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rare hematology market includes revenues earned by entities through genetic testing, disease monitoring, blood transfusion support, patient care management, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rare Hematology Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rare hematology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rare hematology ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rare hematology market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Disease Type: Hemophilia; Sickle Cell Disease; Thalassemia; Myelodysplastic Syndromes; Other Disease Types
  • 2) By Treatment Type: Gene Therapy; Stem Cell Transplantation; Blood Transfusion; Pharmacotherapy
  • 3) By Diagnostic Technique: Laboratory Tests; Blood Tests; Bone Marrow Biopsies; Imaging Techniques; Magnetic Resonance Imaging (MRI) Scans; Ultrasounds; Genetic Testing; Carrier Screening; Whole Genome Sequencing
  • 4) By Application: Pediatric; Adult
  • 5) By End-User: Hospitals; Specialty Clinics; Research Institutes
  • Subsegments:
  • 1) By Hemophilia: Hemophilia A; Hemophilia B; Hemophilia C; Acquired Hemophilia
  • 2) By Sickle Cell Disease: Sickle Cell Anemia; Sickle Hemoglobin C Disease; Sickle Beta Thalassemia
  • 3) By Thalassemia: Alpha Thalassemia; Beta Thalassemia
  • 4) By Myelodysplastic Syndromes: Refractory Anemia (RA); Refractory Anemia With Ring Sideroblasts (RARS); Refractory Cytopenia With Multilineage Dysplasia (RCMD); Refractory Anemia With Excess Blasts (RAEB); Myelodysplastic Syndrome With Isolated Del(5Q); Unclassified Myelodysplastic Syndromes
  • 5) By Other Disease Types: Aplastic Anemia; Paroxysmal Nocturnal Hemoglobinuria; Rare Coagulation Disorders
  • Companies Mentioned: F. Hoffmann-La Roche Ltd; Pfizer Inc.; Abbvie Inc.; Bayer AG; Sanofi S.A.; Novartis AG; Astrazeneca Plc; Bristol-Myers Squibb Company; Takeda Pharmaceutical Company Limited; Amgen Inc.; CSL Behring LLC; Biogen Inc.; Jazz Pharmaceuticals Plc; Octapharma AG; PharmaEssentia Corporation; Disc Medicine Inc.; BioInvent International AB; Mustang Bio Inc.; BlueSphere Bio Inc.; Rallybio LLC
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rare Hematology Market Characteristics

3. Rare Hematology Market Trends And Strategies

4. Rare Hematology Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Rare Hematology Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Rare Hematology PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Rare Hematology Market Growth Rate Analysis
  • 5.4. Global Rare Hematology Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Rare Hematology Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Rare Hematology Total Addressable Market (TAM)

6. Rare Hematology Market Segmentation

  • 6.1. Global Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hemophilia
  • Sickle Cell Disease
  • Thalassemia
  • Myelodysplastic Syndromes
  • Other Disease Types
  • 6.2. Global Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Gene Therapy
  • Stem Cell Transplantation
  • Blood Transfusion
  • Pharmacotherapy
  • 6.3. Global Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Laboratory Tests
  • Blood Tests
  • Bone Marrow Biopsies
  • Imaging Techniques
  • Magnetic Resonance Imaging (MRI) Scans
  • Ultrasounds
  • Genetic Testing
  • Carrier Screening
  • Whole Genome Sequencing
  • 6.4. Global Rare Hematology Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pediatric
  • Adult
  • 6.5. Global Rare Hematology Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Research Institutes
  • 6.6. Global Rare Hematology Market, Sub-Segmentation Of Hemophilia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Acquired Hemophilia
  • 6.7. Global Rare Hematology Market, Sub-Segmentation Of Sickle Cell Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Sickle Cell Anemia
  • Sickle Hemoglobin C Disease
  • Sickle Beta Thalassemia
  • 6.8. Global Rare Hematology Market, Sub-Segmentation Of Thalassemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alpha Thalassemia
  • Beta Thalassemia
  • 6.9. Global Rare Hematology Market, Sub-Segmentation Of Myelodysplastic Syndromes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Refractory Anemia (RA)
  • Refractory Anemia With Ring Sideroblasts (RARS)
  • Refractory Cytopenia With Multilineage Dysplasia (RCMD)
  • Refractory Anemia With Excess Blasts (RAEB)
  • Myelodysplastic Syndrome With Isolated Del(5Q)
  • Unclassified Myelodysplastic Syndromes
  • 6.10. Global Rare Hematology Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Aplastic Anemia
  • Paroxysmal Nocturnal Hemoglobinuria
  • Rare Coagulation Disorders

7. Rare Hematology Market Regional And Country Analysis

  • 7.1. Global Rare Hematology Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Rare Hematology Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rare Hematology Market

  • 8.1. Asia-Pacific Rare Hematology Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rare Hematology Market

  • 9.1. China Rare Hematology Market Overview
  • 9.2. China Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rare Hematology Market

  • 10.1. India Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rare Hematology Market

  • 11.1. Japan Rare Hematology Market Overview
  • 11.2. Japan Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rare Hematology Market

  • 12.1. Australia Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rare Hematology Market

  • 13.1. Indonesia Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rare Hematology Market

  • 14.1. South Korea Rare Hematology Market Overview
  • 14.2. South Korea Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rare Hematology Market

  • 15.1. Western Europe Rare Hematology Market Overview
  • 15.2. Western Europe Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rare Hematology Market

  • 16.1. UK Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rare Hematology Market

  • 17.1. Germany Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rare Hematology Market

  • 18.1. France Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rare Hematology Market

  • 19.1. Italy Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rare Hematology Market

  • 20.1. Spain Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rare Hematology Market

  • 21.1. Eastern Europe Rare Hematology Market Overview
  • 21.2. Eastern Europe Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rare Hematology Market

  • 22.1. Russia Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rare Hematology Market

  • 23.1. North America Rare Hematology Market Overview
  • 23.2. North America Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rare Hematology Market

  • 24.1. USA Rare Hematology Market Overview
  • 24.2. USA Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rare Hematology Market

  • 25.1. Canada Rare Hematology Market Overview
  • 25.2. Canada Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rare Hematology Market

  • 26.1. South America Rare Hematology Market Overview
  • 26.2. South America Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rare Hematology Market

  • 27.1. Brazil Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rare Hematology Market

  • 28.1. Middle East Rare Hematology Market Overview
  • 28.2. Middle East Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rare Hematology Market

  • 29.1. Africa Rare Hematology Market Overview
  • 29.2. Africa Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rare Hematology Market Competitive Landscape And Company Profiles

  • 30.1. Rare Hematology Market Competitive Landscape
  • 30.2. Rare Hematology Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Rare Hematology Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Astrazeneca Plc
  • 31.3. Bristol-Myers Squibb Company
  • 31.4. Takeda Pharmaceutical Company Limited
  • 31.5. Amgen Inc.
  • 31.6. CSL Behring LLC
  • 31.7. Biogen Inc.
  • 31.8. Jazz Pharmaceuticals Plc
  • 31.9. Octapharma AG
  • 31.10. PharmaEssentia Corporation
  • 31.11. Disc Medicine Inc.
  • 31.12. BioInvent International AB
  • 31.13. Mustang Bio Inc.
  • 31.14. BlueSphere Bio Inc.
  • 31.15. Rallybio LLC

32. Global Rare Hematology Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rare Hematology Market

34. Recent Developments In The Rare Hematology Market

35. Rare Hematology Market High Potential Countries, Segments and Strategies

  • 35.1 Rare Hematology Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Rare Hematology Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Rare Hematology Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer